Literature DB >> 1762381

[Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?].

C Wüster1, E Slenczka, R Ziegler.   

Abstract

In a retrospective study of 632 patients with pituitary disease we diagnosed pituitary insufficiency without hypersecretion of any pituitary hormone in 122 patients. Patients were substituted with sex hormones (76%), hydrocortisone (74%) and/or L-thyroxine (77%). 76% had additional growth hormone deficiency, as shown by an increase of growth hormone of less than 5 ng/ml after i.v. administration of L-arginine. In 17% of all patients the diagnosis of osteoporosis was proven or suspected radiologically. 57% had low bone mass of lumbar spine (dualphotonabsorptiometry) and 73% had low bone mass of the proximal forearm (singlephotonabsorptiometry). BMD values of pituitary insufficient patients were in the same range as those of patients with established osteoporosis. More than half of all patients (53%) complained of tiredness, exhaustion and muscle weakness. 40% suffered from adipositas. 77% had hyperlipidemia (68% hypertriglyceridemia and 42% hypercholesterinemia), 18% had hypertension. 14% of the patients had arteriosclerotic events in their history (myocardial infarction or stroke). These figures are higher than incidences shown in the German PROCAM-study. These data show an increased prevalence of osteoporosis and vascular diseases. This is in contrast to the general opinion, that patients with pituitary insufficiency are adequately treated by substitution with adrenal, thyroid and sex hormones. Whether other factors such as the additional growth hormone deficiency are responsible for these diseases has to be examined in prospective studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1762381     DOI: 10.1007/bf01797616

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  5 in total

1.  Physical and psychological capabilities during substitution therapy with recombinant growth hormone in adults with growth hormone deficiency.

Authors:  M Degerblad; O Almkvist; R Grunditz; K Hall; L Kaijser; E Knutsson; H Ringertz; M Thorén
Journal:  Acta Endocrinol (Copenh)       Date:  1990-08

2.  Beneficial effects of growth hormone treatment in GH-deficient adults.

Authors:  J O Jørgensen; S A Pedersen; L Thuesen; J Jørgensen; T Ingemann-Hansen; N E Skakkebaek; J S Christiansen
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

3.  Effects of human growth hormone in men over 60 years old.

Authors:  D Rudman; A G Feller; H S Nagraj; G A Gergans; P Y Lalitha; A F Goldberg; R A Schlenker; L Cohn; I W Rudman; D E Mattson
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

4.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

5.  The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency.

Authors:  F Salomon; R C Cuneo; R Hesp; P H Sönksen
Journal:  N Engl J Med       Date:  1989-12-28       Impact factor: 91.245

  5 in total
  14 in total

Review 1.  Growth hormone deficiency in the adult.

Authors:  M Doga; S Bonadonna; M Gola; G Mazziotti; A Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1.

Authors:  P H Kann; D Bartsch; P Langer; J Waldmann; P Hadji; A Pfützner; J Klüsener
Journal:  J Endocrinol Invest       Date:  2011-07-27       Impact factor: 4.256

3.  Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients.

Authors:  S Longobardi; F Di Rella; R Pivonello; C Di Somma; M Klain; L Maurelli; R Scarpa; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

4.  Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study.

Authors:  R H Böger; C Skamira; S M Bode-Böger; G Brabant; A von zur Muhlen; J C Frolich
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

Review 5.  [Growth hormone therapy in adult patients: a review].

Authors:  Peter Herbert Kann
Journal:  Wien Klin Wochenschr       Date:  2011-05-18       Impact factor: 1.704

6.  Sex differences in the prevalence of metabolic syndrome and its components in hypopituitary patients: comparison with an age- and sex-matched nationwide control group.

Authors:  Ah Reum Khang; Eu Jeong Ku; Ye An Kim; Eun Roh; Jae Hyun Bae; Tae Jung Oh; Sang Wan Kim; Chan Soo Shin; Seong Yeon Kim; Jung Hee Kim
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

7.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

8.  [Reduced incidence of side-effects of growth hormone substitution in 404 patients with hypophyseal insufficiency. Results of a multicenter indications study].

Authors:  C Wüster; U Melchinger; T Eversmann; J Hensen; P Kann; A von zur Mühlen; M B Ranke; H Schmeil; H Steinkamp; U Tuschy
Journal:  Med Klin (Munich)       Date:  1998-10-15

9.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

10.  Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression.

Authors:  M Rudling; B Angelin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.